FOXP3 and neoplasm: Enabling tumor progression, activated CD4+Foxp3+ regulatory T cells (Tregs) are known to migrate to the tumor site and inhibit of CD8 effector T cells (Teffs), which are mainly responsible for anti-tumor immune responses [69].